SNY Jul 2024 50.000 put
| Previous Close | 2.5500 |
| Open | 2.2000 |
| Bid | 2.2000 |
| Ask | 2.6500 |
| Strike | 50.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 2.1500 - 2.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 173 |
Simply Wall St.3 Top Euronext Paris Dividend Stocks With Yields From 4% To 5.1%
Amid a backdrop of modestly rising European markets and easing monetary policies, investors are increasingly looking for stable returns in a fluctuating economic landscape. In this context, dividend stocks listed on Euronext Paris offer an appealing blend of yield and potential resilience, making them worthy of consideration for those seeking income-generating investments.
GlobeNewswireDupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only treatment indicated for EoE in the U.S. for this age group TARRYTOWN, N.Y. and PARIS, June 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine (NEJM) has published results from a positive Phase 3 trial for Dupixent
GlobeNewswirePress Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one yearDupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group Paris and Tarrytown, NY, June 26, 2024. The New England Journal of Medicine has published results from a positive pha
